Cite

    Becker, R. et al. (n.d.). Lixisenatide resensitizes the insulin‐secretory response to intravenous glucose challenge in people with type 2 diabetes – a study in both people with type 2 diabetes and healthy subjects1. Diabetes, obesity & metabolism. 16 (9), pp. 793-800. [Online].